| Company | FY | Global CapEx ($mm) | U.S. assets ($mm) | Total geo assets ($mm) | U.S. asset share | Derived U.S. CapEx ($mm) | Notes |
| Merck & Co. | FY25 (Dec) | 4,112 | 15,021 | 25,316 | 59.3% | 2,440 | |
| Johnson & Johnson | FY25 (Dec) | 4,832 | 89,392 | 1,99,210 | 44.9% | 2,168 | Denominator is total geographic assets (full balance sheet) |
| GlaxoSmithKline | FY25 (Dec) | 1,814 | 19,545 | 45,724 | 42.7% | 776 | |
| Lonza | FY25 (Dec) | 1,666 | CapIQ geo assets unreliable (US shows $1.3mm); US share needs annual-report source | ||||
| Takeda | FY ended Mar-2025 | 1,341 | 51,119 | 73,291 | 69.7% | 935 | Off-December fiscal year (Mar-2025) |
| Pfizer | FY25 (Dec) | 2,629 | 9,680 | 19,317 | 50.1% | 1,317 | |
| Eli Lilly | FY25 (Dec) | 7,841 | 18,764 | 26,601 | 70.5% | 5,531 | US numerator is ‘U.S. and Puerto Rico’ |
| AstraZeneca | FY25 (Dec) | 2,810 | 42,201 | 1,14,074 | 37.0% | 1,040 | Numerator is ‘The Americas’ per slide footnote 2; CapEx is PP&E only (excl software intangibles) |
| Bristol-Myers Squibb | FY25 (Dec) | 1,311 | 4,931 | 7,543 | 65.4% | 857 | |
| CSL Limited | FY ended Jun-2025 | 636 | 4,347 | 17,917 | 24.3% | 154 | Off-December fiscal year (Jun-2025); asset base heavily Switzerland-weighted |
| Bayer | FY25 (Dec) | 2,920 | 40,794 | 72,012 | 56.6% | 1,654 | Group-wide CapEx (Crop Science + Pharma + Consumer Health), not pharma-only |
| Company | Geography | Project description | Source link |
| Eli Lilly | Lehigh Valley, PA, USA | $3.5b+ injectable medicine and device facility (announced Jan 2026) to produce next-gen weight-loss therapies including retatrutide; Lilly’s 10th US site since 2020 | https://investor.lilly.com/news-releases/news-release-details/lilly-selects-pennsylvania-home-its-newest-injectable-medicine |
| Pfizer | United States (multi-site) | $70b committed to US R&D, manufacturing and capital projects over the next few years (announced Sept 2025), building on $83b invested 2018–2024 | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaches-landmark-agreement-us-government-lower-drug |
| Johnson & Johnson | Montgomery County, PA, USA | $1b+ next-generation cell therapy facility (announced Feb 2026); 500 biomanufacturing jobs; part of $55b US investment commitment through 2029 | https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-footprint-with-more-than-1-billion-investment-in-next-generation-cell-therapy-manufacturing-facility-in-pennsylvania |
| Roche / Genentech | Holly Springs, NC, USA | Doubled Holly Springs investment to ~$2b (announced Jan 2026) to expand obesity-drug manufacturing; first East Coast Genentech site; operational by 2029 | https://www.gene.com/media/press-releases/15096/2026-01-20/genentech-more-than-doubles-investment-i |
| Eli Lilly | Goochland County, VA, USA | $5b facility announced Sept 2025; Lilly’s first fully integrated API + drug product site for its bioconjugate platform and monoclonal antibody portfolio, incl. antibody-drug conjugates (ADCs); 650 jobs; first of four new US sites | https://investor.lilly.com/news-releases/news-release-details/lilly-announces-plans-build-5-billion-manufacturing-facility |
| Merck & Co. | Elkton, VA, USA | $3b, 400,000 sq ft small-molecule manufacturing facility (Center of Excellence), ground broken Oct 2025; 500 jobs; part of $70b+ US investment; production by 2029 | https://www.merck.com/news/merck-breaks-ground-on-3-billion-center-of-excellence-for-pharmaceutical-manufacturing-in-elkton-virginia/ |
| Johnson & Johnson | Wilson, NC, USA | $2b biologics manufacturing facility, ground broken Mar 2025; flagship project of $55b US investment commitment through 2029; produces medicines for cancer and immune-mediated disease | https://www.jnj.com/media-center/press-releases/johnson-johnson-increases-u-s-investment-to-more-than-55-billion-over-the-next-four-years |
| Roche / Genentech | Holly Springs, NC, USA | $700m+ Genentech manufacturing facility (announced May 2025, broke ground Aug 2025); first East Coast Genentech site; produces next-gen obesity/metabolic medicines; part of $50b US commitment | https://www.roche.com/media/releases/med-cor-2025-08-25 |
| Company | Geography | Project description | Source link |
| Eli Lilly | Goochland County, VA, USA | $5b facility announced Sept 2025; Lilly’s first fully integrated API + drug product site for its bioconjugate platform and monoclonal antibody portfolio, incl. antibody-drug conjugates (ADCs); 650 jobs; first of four new US sites | https://investor.lilly.com/news-releases/news-release-details/lilly-announces-plans-build-5-billion-manufacturing-facility |
| Merck & Co. | Elkton, VA, USA | $3b, 400,000 sq ft small-molecule manufacturing facility (Center of Excellence), ground broken Oct 2025; 500 jobs; part of $70b+ US investment; production by 2029 | https://www.merck.com/news/merck-breaks-ground-on-3-billion-center-of-excellence-for-pharmaceutical-manufacturing-in-elkton-virginia/ |
| Johnson & Johnson | Wilson, NC, USA | $2b biologics manufacturing facility, ground broken Mar 2025; flagship project of $55b US investment commitment through 2029; produces medicines for cancer and immune-mediated disease | https://www.jnj.com/media-center/press-releases/johnson-johnson-increases-u-s-investment-to-more-than-55-billion-over-the-next-four-years |
| Roche / Genentech | Holly Springs, NC, USA | $700m+ Genentech manufacturing facility (announced May 2025, broke ground Aug 2025); first East Coast Genentech site; produces next-gen obesity/metabolic medicines; part of $50b US commitment | https://www.roche.com/media/releases/med-cor-2025-08-25 |
| Novo Nordisk | Clayton, NC, USA | $4.1b second fill-finish facility (announced 2024); ~1.4m sq ft for injectables incl. Ozempic and Wegovy; phased buildout 2027–2029; one of Novo’s largest-ever investments | https://www.fiercepharma.com/manufacturing/novo-obesity-drug-plant-expand-wegovy-lilly-zepbound |
| Eli Lilly | Goochland County, VA, USA | Lilly announced a $5b facility in September 2025 for API and drug product manufacturing across its bioconjugate platform and monoclonal antibody portfolio, including antibody-drug conjugates. |
| Merck & Co. | Elkton, VA, USA | Merck broke ground in October 2025 on a $3b small-molecule manufacturing facility, with production expected by 2029. |
| Johnson & Johnson | Wilson, NC, USA | J&J broke ground in March 2025 on a $2b biologics manufacturing facility producing medicines for cancer and immune-mediated disease. |
| Roche / Genentech | Holly Springs, NC, USA | Genentech announced a facility of more than $700m in May 2025 to produce next-generation obesity and metabolic medicines, and broke ground in August 2025. |
| Novo Nordisk | Clayton, NC, USA | Novo announced a $4.1b fill-finish facility in 2024 for injectable medicines including Ozempic and Wegovy, with buildout expected to complete between 2027 and 2029. |